The sole influenza vaccine made in cell culture in the United States may have worked about 20 percent better this flu season than the standard vaccines made in eggs, Food and Drug Administration Commissioner Scott Gottlieb said Thursday.

Gottlieb revealed that figure in a hearing of the congressional subcommittee on oversight and investigations, called to explore this year’s severe flu season and why flu vaccines did not appear to protect especially well.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Was Flucelvax used in the Medicare population noted in the above article the senior high dose or the regular dose? Your article does not state. I can’t find anyone who administers the senior dose in my area. Why with all the baby boomers aren’t doctors offering the senior dose also? Thanks.

  • The 20% is relative increase, not absolute increase in percentage points. So 17% vaccine efficacy for egg-based becomes about 20% vaccine efficacy for cell-based. Any increase is good, but this is a far cry from what you’re reporting.

  • I got the egg free version of the flu vaccine this season due to egg allergy. The difficulty was that I had to travel for miles to get it. A few years ago, Target made it available but when CVS bought Target pharmacies, this version was dropped. I wish this were more widely available.

  • Great article…. I think you will be quite interested in the upcoming (14th) conference call by Novavax, the innovator of NanoFlu vaccine using nanoparticle platform…
    Nanoflu was briefly mentioned in yesterdays congressional conference…

    NanoFlu had a phase 1/2 trial and moving on to phase 2 (total) and Phase 3…

    https://mail.aol.com/webmail-std/en-us/suite

    Novavax has a maternal RSV vaccine (recombinent) in phase III as well…

    Best regards… Dick Swift (photographer)
    La Crosse, WI

  • May I observe that I don’t agree with the math here? “But if the cell-culture vaccine were 20 percent better than the flu shots made in eggs, an additional 17 people — 20 percent of the 83 — would have been protected.”
    If the alternate were 20% better then an additional 4 people (20% of the 17) – so 21 – would have been protected. That is how I read it but you have the primary material.

  • I always get the egg free flu shot as I am allergic to eggs and so far for the last 5 years have no flu.😊

Your daily dose of news in health and medicine

Privacy Policy